Opus Genetics, Inc. (IRD) Cash Flow Statement
Opus Genetics, Inc. (IRD) generated -$40.7M of operating cash flow over the twelve months to 2026-06-30, spent -$5.4M on capital expenditure and had free cash flow of -$35.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IRDOpus Genetics, Inc.Follow IRD — free
—
Price chart with a free account
- Market cap
- 288.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2019 Dec 19 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -3.6 | -19.4 | 14.3 | -1.1 | -25.6 | -35.3 | -40.7 | |
| Capital expenditure | 0.0 | — | — | — | 0.0 | 0.0 | 5.4 | |
| Free cash flow | -3.6 | — | — | — | -25.6 | -35.3 | -35.3 | |
| Stock-based compensation | 0.3 | 1.9 | 1.8 | 3.5 | 3.4 | 3.4 | — |
USD millions · SEC XBRL
Opus Genetics, Inc. — questions
- What is Opus Genetics, Inc.'s operating cash flow?
- -$40.7M over the twelve months to 2026-06-30.
- How much does Opus Genetics, Inc. spend on capital expenditure?
- -$5.4M over the twelve months to 2026-06-30.
- What is Opus Genetics, Inc.'s free cash flow?
- -$35.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Opus Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.